A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib.

Trial Profile

A Phase 2 Study of XL647 in Subjects With Non-Small Cell Lung Cancer Who Have Progressed After Responding to Treatment With Either Gefitinib or Erlotinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2012

At a glance

  • Drugs Tesevatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Exelixis; Symphony Evolution
  • Most Recent Events

    • 17 Oct 2011 Kadmon Corporation as trial sponsor and lead centre added as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top